10.6微米激光灸治疗糖尿病周围神经病变:双盲随机对照试验
这项双盲随机对照试验将68例糖尿病周围神经病变患者按1:1分为激光灸组和假激光灸组,每周3次共12次治疗。结果显示激光灸组在改善MNSI评分和DSQL评分方面优于假激光灸组,未记录严重不良事件。
要点
- 激光灸可改善糖尿病周围神经病变患者的临床症状和生活质量。
- 激光灸在改善生活质量方面优于假激光灸。
- 未记录严重不良事件。
核心结论
- 10.6微米激光灸治疗改善了糖尿病周围神经病变患者的临床症状和生活质量。
研究设计与样本
- 双盲随机对照试验,68例糖尿病周围神经病变患者按1:1随机分为激光灸组和假激光灸组,每周3次共12次治疗。
- 在基线、治疗第2周和第4周、治疗后第4周和第8周(即第8周和第12周)评估MNSI评分、DSQL评分、神经传导速度和血液流变学参数。
主要发现
- 两组MNSI评分在各时间点均较基线显著降低(P < 0.01),DSQL评分在第4、8、12周较基线显著降低(P < 0.001)。
- 激光灸组在第4周MNSI评分低于假激光灸组(P < 0.05),在第4、8、12周DSQL评分低于假激光灸组(P < 0.05)。
- 第4周时两组间神经传导速度无显著差异(P > 0.05)。
- 治疗后各组血液流变学参数与基线比较无显著差异(P > 0.05),但激光灸组全血高切还原粘度和红细胞刚性指数显著低于假激光灸组(P < 0.01)。
- 未记录严重不良事件。
临床怎么用
- 对于糖尿病周围神经病变患者,可考虑使用10.6微米激光灸以改善临床症状和生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To observe the clinical effects of 10.6-μm laser moxibustion (LM) on diabetic peripheral neuropathy (DPN) and quality of life in patients. METHODS: Sixty-eight patients with DPN were randomly assigned to two groups in a 1:1 ratio and received LM or sham LM 3 times/week for a total of 12 treatments. Outcome parameters were assessed at baseline, at Weeks 2 and 4 of treatment, and at 4 and 8 weeks post-treatment (Weeks 8 and 12) using Michigan Neuropathy Screening Instrument (MNSI) and Diabetes-Specific Quality of Life (DSQL) scores, nerve conduction velocity (NCV), and blood rheology parameters. RESULTS: Most (58/68) patients completed the trial. MNSI scores were significantly lower at every time point (P < 0.01), and DSQL scores were significantly lower at Weeks 4, 8, and 12 (P < 0.001), compared with baseline in both groups. The LM group had lower MNSI scores at Week 4 (P < 0.05), and lower DSQL scores at Weeks 4, 8, and 12 (P < 0.05) compared with the sham LM group. At Week 4, there was no significant between-group difference in NCV (P > 0.05). Post-treatment, there were no significant differences in blood rheology parameters compared with baseline within each group (P > 0.05). Whole blood high-shear reductive viscosity and red blood cell rigidity index were significantly lower in the LM group than in the sham LM group (P < 0.01). No serious adverse events were recorded. CONCLUSION: Treatment with 10.6-μm LM improved clinical symptoms and quality of life in patients with DPN. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000029329. Registered 25 January 2020, https://www.chictr.org.cn/showproj.html?proj=48490.
引用
- Yin Y, Huang Z, Li Y, et al. Effectiveness of 10.6-μm laser therapy for diabetic peripheral neuropathy: A double-blind, randomized controlled trial. Complement Ther Med. 2025. PMID: 41093021. doi:10.1016/j.ctim.2025.103259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。